Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

ANS Seeks Neuromodulation Remedy For Migraine Headaches

This article was originally published in The Gray Sheet

  • News

Executive Summary

ANS plans to seek approval to use its neuromodulation platform to treat migraine headaches, according to CEO Chris Chavez

You may also be interested in...



House Bill Would Create Pain Center Within NIH, Raise Awareness

Legislation introduced in Congress could help increase demand for chronic pain devices marketed by companies like Medtronic, St. Jude Medical/Advanced Neuromodulation Systems and Boston Scientific

House Bill Would Create Pain Center Within NIH, Raise Awareness

Legislation introduced in Congress could help increase demand for chronic pain devices marketed by companies like Medtronic, St. Jude Medical/Advanced Neuromodulation Systems and Boston Scientific

St. Jude Expects Easy Enrollment In New PFO Study For Migraines

St. Jude Medical expects the trial of its Premere patent foramen ovale (PFO) closure device in migraine patients to enroll patients faster than trials of PFO closure to prevent stroke

Table

View full table

Tags:
Latest Headlines

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion

Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations

Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application

See All
UsernamePublicRestriction

Register

MT022449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By